-
EP2464349
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP2464349
| EP2464349 - USE OF PPAR DELTA LIGANDS FOR THE TREATMENT OR PREVENTION OF INFLAMMATION OR ENERGY METABOLISM/PRODUCTION RELATED DISEASES [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 26.12.2014 Database last updated on 15.06.2024 | Most recent event Tooltip | 26.12.2014 | Application deemed to be withdrawn | published on 28.01.2015 [2015/05] | Applicant(s) | For all designated states Cerenis Therapeutics Holding S.A. Rue de la Decouverte BP 87519 31675 Labege Cedex / FR | For all designated states Nippon Chemiphar Co., Ltd. 2-2-3, Iwamoto-cho, Chiyoda-ku Tokyo 101-0032 / JP | [2013/02] |
| Former [2012/25] | For all designated states Cerenis Therapeutics S.A. Rue de la Decouverte BP 87519 31675 Labege Cedex / FR | ||
| For all designated states Nippon Chemiphar Co., Ltd. 2-2-3, Iwamoto-cho, Chiyoda-ku Tokyo 101-0032 / JP | Inventor(s) | 01 /
BARBARAS, Ronald 22 Bis Avenue Du Grand Plantier F-31840 Seilh / FR | 02 /
ONICIU, Daniela, Carmen 5 Rue Adrien De Gaston F-31130 Balma / FR | 03 /
DASSEUX, Jean-louis 7 Allées Charles Malpel Bat. B 406 F-31300 Toulouse / FR | 04 /
SCOTT, Robert, A. 9 Chemin Du Barri F-31179 Rouffiac-tolosan / FR | 05 /
WETTERAU, John, R. 5560 Crest Court Dexter MI 48130 / US | [2012/25] | Representative(s) | Savic, Bojan, et al Jones Day Rechtsanwälte Attorneys-at-Law Patentanwälte Prinzregentenstrasse 11 80538 München / DE | [2013/52] |
| Former [2012/25] | Ritter, Thomas Kurt Jones Day Prinzregentenstrasse 11 80538 München / DE | Application number, filing date | 10744819.3 | 13.08.2010 | WO2010US45450 | Priority number, date | US20090234231P | 14.08.2009 Original published format: US 234231 P | US20090251655P | 14.10.2009 Original published format: US 251655 P | [2012/25] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2011020001 | Date: | 17.02.2011 | Language: | EN | [2011/07] | Type: | A2 Application without search report | No.: | EP2464349 | Date: | 20.06.2012 | Language: | EN | The application published by WIPO in one of the EPO official languages on 17.02.2011 takes the place of the publication of the European patent application. | [2012/25] | Search report(s) | International search report - published on: | EP | 07.04.2011 | Classification | IPC: | A61K31/381, A61K31/382, A61K31/42, A61K31/421, A61K31/422, A61K31/426 | [2012/25] | CPC: |
A61K31/381 (EP,KR,US);
A61K31/382 (EP,KR,US);
A61K31/42 (EP,US);
A61K31/421 (EP,US);
A61K31/422 (EP,KR,US);
A61K31/426 (EP,KR,US);
A61P1/04 (EP);
A61P11/00 (EP);
A61P11/06 (EP);
A61P13/12 (EP);
A61P17/02 (EP);
A61P17/14 (EP);
A61P19/02 (EP);
A61P21/00 (EP);
A61P25/00 (EP);
A61P25/08 (EP);
A61P25/28 (EP);
A61P27/02 (EP);
A61P27/16 (EP);
A61P29/00 (EP);
A61P3/04 (EP);
A61P3/06 (EP);
A61P3/08 (EP);
A61P3/10 (EP);
A61P37/02 (EP);
A61P43/00 (EP);
A61P5/50 (EP);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR [2012/25] | Title | German: | VERWENDUNG VON PPAR-DELTA-LIGANDEN FÜR DIE BEHANDLUNG ODER PRÄVENTION VON ENTZÜNDUNGEN ODER ENERGIESTOFFWECHSEL-/PRODUKTIONSBEDINGTEN ERKRANKUNGEN | [2012/25] | English: | USE OF PPAR DELTA LIGANDS FOR THE TREATMENT OR PREVENTION OF INFLAMMATION OR ENERGY METABOLISM/PRODUCTION RELATED DISEASES | [2012/25] | French: | UTILISATION DES LIGANDS PPAR DANS LE TRAITEMENT OU LA PRÉVENTION D'INFLAMMATIONS OU DE MALADIES ASSOCIÉES AU MÉTABOLISME/PRODUCTION ÉNERGÉTIQUE | [2012/25] | Entry into regional phase | 14.02.2012 | National basic fee paid | 14.02.2012 | Designation fee(s) paid | 14.02.2012 | Examination fee paid | Examination procedure | 14.02.2012 | Examination requested [2012/25] | 19.09.2012 | Amendment by applicant (claims and/or description) | 04.04.2014 | Despatch of a communication from the examining division (Time limit: M04) | 15.08.2014 | Application deemed to be withdrawn, date of legal effect [2015/05] | 08.09.2014 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2015/05] | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 04.04.2014 | Fees paid | Renewal fee | 10.08.2012 | Renewal fee patent year 03 | 19.08.2013 | Renewal fee patent year 04 | Penalty fee | Additional fee for renewal fee | 31.08.2014 | 05 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [I]WO0228434 (GLAXO GROUP LTD [GB], et al) [I] 1-13 * page 2, paragraph l - page 3, paragraph 1 *; | [Y]WO0228433 (GLAXO GROUP LTD [GB], et al) [Y] 1-15 * page 3 *; | [XI]WO0250048 (GLAXO GROUP LTD [GB], et al) [X] 2-5,8,11-13 * example 3 * [I] 1,6,7,9,10; | [XI]EP1424330 (NIPPON CHEMIPHAR CO [JP]) [X] 2-5,8,11-13 * paragraph [0022] * * table 1 * [I] 1,6,7,9,10; | [Y]WO2007047431 (KALYPSYS INC [US], et al) [Y] 1-13 * page 5 * * pages 10,11 *; | [Y]WO2007056496 (IRM LLC [US], et al) [Y] 1-15 * claim 9 * * compounds B2, B3 *; | [XI]US2007225294 (BANKER PIERETTE [US], et al) [X] 2-5,8,11-13 * claim 1 * * paragraph [0036] * [I] 1,6,7,9,10; | [X]EP1854784 (NIPPON CHEMIPHAR CO [JP]) [X] 2-5,8,11,12 * paragraphs [0009] , [0010] , [0011] , [0067] *; | [XI]EP1897872 (NIPPON CHEMIPHAR CO [JP]) [X] 2-5,8,11-13 * claim 1 * [I] 1,9,10; | [XI]FR2910893 (GENFIT SA [FR]) [X] 1-5,8,11-13 * page 5; compound (I) * * compound 28 * * page 4 * * claim 23 * [I] 6,7,9,10; | [XI]WO2008154023 (CERENIS THERAPEUTICS S A [FR], et al) [X] 2-5,8,11-13 * example - * * paragraph [0012] * [I] 1,6,7,9,10; | [Y] - LETAVERNIER EMMANUEL ET AL, "Peroxisome proliferator-activated receptor beta/delta exerts a strong protection from ischemic acute renal failure", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, (200508), vol. 16, no. 8, ISSN 1046-6673, pages 2395 - 2402, XP002602232 [Y] 6 * page 2401, paragraph l * DOI: http://dx.doi.org/10.1681/ASN.2004090802 | [YD] - KARNIK PRATIMA ET AL, "Hair Follicle Stem Cell-Specific PPAR gamma Deletion Causes Scarring Alopecia", JOURNAL OF INVESTIGATIVE DERMATOLOGY, (200905), vol. 129, no. 5, ISSN 0022-202X, pages 1243 - 1257, XP002602233 [YD] 9 * abstract * DOI: http://dx.doi.org/10.1038/JID.2008.369 | [Y] - FAIOLA BRENDA ET AL, "PPAR alpha, more than PPAR delta, mediates the hepatic and skeletal muscle alterations induced by the PPAR agonist GW0742", TOXICOLOGICAL SCIENCES, (200810), vol. 105, no. 2, ISSN 1096-6080, pages 384 - 394, XP002602234 [Y] 7 * abstract * DOI: http://dx.doi.org/10.1093/TOXSCI/KFN130 | [Y] - MICHALIK L ET AL, "Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)alpha and PPARbeta mutant mice", THE JOURNAL OF CELL BIOLOGY, ROCKEFELLER UNIVERSITY PRESS, US LNKD- DOI:10.1083/JCB.200011148, (20010820), vol. 154, no. 4, ISSN 0021-9525, pages 799 - 814, XP002234137 [Y] 10 * abstract * DOI: http://dx.doi.org/10.1083/jcb.200011148 | by applicant | US4328245 | US4409239 | US4410545 | US5612059 | US6350458 | WO0217918 | US6787552 | US7078422 | US7119104 | US7265137 | US7402597 | - ISSEMAN ET AL., NATURE, (1990), vol. 347, pages 645 - 650 | - PROC. NATL. ACAD. SCI. USA, (1994), vol. 91, pages 7335 - 7359 | - C. FIELDING, BIOCHEMISTRY, (1988), vol. 27, no. L, pages 25 - 29 | - JAMA, (2003), vol. 290, no. 17, pages 2292 - 2300 | - JAMA, (2007), vol. 297, no. 15, pages 1675 - 1678 | - STEEG ET AL., JACC, (2008), vol. 51, pages 634 - 643 | - J. LEUKOC. BIOL., (2009), vol. 86 | - PORTILLA ET AL., AM J. PHYSIOL. RENAL PHYSIOL., (2000), vol. 278, pages F667 - F675 | - SIVARAJAH ET AL., AM. J. NEPHROL., (2003), vol. 23, pages 267 - 276 | - LETAVERNIER ET AL., J. AM. SOC. NEPHROL., (2005), vol. 16, pages 2395 - 2402 | - MICHALIK, L., J. CELL BIOL, (2001), vol. 154, no. 4, pages 799 - 814 | - KAMIK ET AL., J. INVESTIGATIVE DERMATOLOGY, (2009), vol. 129, pages 1243 - 1257 | - FAIOLA ET AL., TOXICOL. SCI., (2008), vol. 105, pages 384 - 394 | - YAO Z ET AL., POSTEPY BIOCHEM., (2008), vol. 54, no. 2, pages 161 - 8 | - PRONICKA E, POSTEPY BIOCHEM., (2008), vol. 54, no. 2, pages 161 - 8 | - BIOCHEM., (1972), vol. 11, pages 942 - 944 | - Modified-Release Drug Deliver Technology, MARCEL DEKKER, INC., (2002), vol. 126 | - SANTUS; BAKER, J CONTROLLED RELEASE, (1995), vol. 35, pages 1 - 21 | - VERMA ET AL., DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, (2000), vol. 26, pages 695 - 708 | - VERMA ET AL., J. CONTROLLED RELEASE, (2002), vol. 79, pages 7 - 27 | - LUQUET S. ET AL., FASEB J, (2003), vol. 17, no. 15, pages 2299 - 301 | - LEHR ET AL., HISTOCHEM CYTOCHEM, (1997), vol. 45, no. 11, pages 1559 - 65 | - J HISTOCHEM CYTOCHEM, (1999), vol. 47, no. 1, pages 119 - 26 | - LEHMANN JM, J BIOL CHEM., (1997), vol. 272, no. 6, pages 3406 - 10 | - FORMAN BM ET AL., CELL, (1995), vol. 81, no. 4, pages 541 - 50 |